15-min delayed · Sep 8, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 11 firms covering Travere Therapeutics Inc, 9 rate it Buy or better, 2 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. The target range is very wide, $25.00 to $85.00 (about 3.4x), which points to deep disagreement over how to value the company rather than near-term timing. The average target of $63.09 sits 5% below the current $66.07. The rating mix has stayed broadly stable, with Buy-side ratings easing from 10 to 9 over recent months. On the fundamentals, the Street sees consensus EPS building from about $1.14 next quarter toward $5.67 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS11 ratings
Strong Buy
Strong Buy00%
Buy982%
Hold218%
Sell00%
Strong Sell00%
Based on 11 analysts giving stock ratings to Travere Therapeutics Inc.
As of Sep, 9 of 10 firms rate TVTX a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
TVTX EPS & revenue forecast
EPS · NEXT QUARTER
$1.14
Range $0.68 – $2.03 · 8 analysts · +208% YoY
Next period, 8 analysts expect Travere Therapeutics Inc to earn $1.14 a share (range $0.68 – $2.03), versus $0.37 a year earlier. Full-year consensus is $1.74, growing to $5.67 the year after.
REVENUE · NEXT QUARTER
$232.1M
Range $180.7M – $274.8M · 8 analysts · +79% YoY
Revenue is expected to reach $232.1M (range $180.7M – $274.8M), +79.0% year-over-year. Full-year consensus is $724.1M, rising to $1.1B next year.
Top analysts covering Travere Therapeutics Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on TVTX.
#1
Laura Chico
Wedbush · Rank #74
Buy
$75.00+13.5% to target
Overall win rate
44%
+ Follow
#2
Anupam Rama
JP Morgan · Rank #75
Buy
$53.00-19.8% to target
Overall win rate
51%
+ Follow
#3
Ed Arce
HC Wainwright & Co. · Rank #132
Buy
$30.00-54.6% to target
Overall win rate
44%
+ Follow
#4
Greg Harrison
Scotiabank · Rank #179
Buy
$31.00-53.1% to target
Overall win rate
38%
+ Follow
#5
Yigal Nochomovitz
Citigroup · Rank #245
Buy
$85.00+28.7% to target
Overall win rate
41%
+ Follow
TVTX stock forecast FAQ
What is TVTX's average 12-month price target?+
The 11 analysts with a live target average $63.09 for Travere Therapeutics Inc over the next 12 months, ranging from a $85.00 high to a $25.00 low.
Is TVTX stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 11 analyst ratings, 9 are Buy or Strong Buy, 2 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for TVTX?+
The Street-high target is $85.00 (Citigroup), and the Street-low is $25.00 (Stifel). The average of all 11 active targets is $63.09.
How many Wall Street analysts cover TVTX?+
11 analysts have an active rating on Travere Therapeutics Inc, and 11 firms carry a live 12-month price target.
Who is the most accurate analyst covering TVTX?+
Among analysts who currently cover TVTX, Laura Chico of Wedbush has the strongest overall Quantellect track record (Rank #74). Their current call is Buy with a $75.00 target.
What is Travere Therapeutics Inc's projected EPS for next quarter?+
The consensus estimate is $1.14 per share (range $0.68 – $2.03) across 8 analysts. Full-year EPS is projected at $1.74, rising to $5.67 the following year.
How much revenue is Travere Therapeutics Inc expected to report next quarter?+
Consensus revenue is $232.1M (range $180.7M – $274.8M). Full-year revenue is projected at $724.1M, growing to $1.1B next year.
Have analysts been upgrading or downgrading TVTX lately?+
As of Sep, 9 of 10 firms rate TVTX a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their TVTX calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
